As previously reported, earlier this year Celltrion, Inc. (“Celltrion”) filed petitions seeking inter partes review (“IPR”) of...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
BiosimilarsIP.com Legal provides analysis of legal decisions from federal courts and from the PTAB related to biologics and biosimilars.
-
-
As we previously reported, Celltrion filed three petitions seeking inter partes review (“IPR”) of two patents related to Genentech and...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On August 8, 2017, Sanofi-Aventis (“Sanofi”) filed a patent infringement suit in the United States District Court for the District of...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Recently, AbbVie, Inc. and AbbVie Biotechnology, LTD (collectively “AbbVie” or “Plaintiffs”) filed a Complaint in the United States...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Since our prior article on the litigation between Amgen and Hospira over Hospira’s proposed biosimilar to Amgen’s Epogen®, there have...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
As we previously reported here, earlier this year the Supreme Court agreed to hear its first case arising under the Biosimilars Price...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The patent venue statue, 28 U.S.C. § 1400(b), states that “ny civil action for patent infringement may be brought in the judicial...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]